Discovery of Chalcone-Based Hybrid Structures as High Affinity and Site-Specific Inhibitors against SARS-CoV-2: A Comprehensive Structural Analysis Based on Various Host-Based and Viral Targets

被引:5
|
作者
Valipour, Mehdi [1 ]
Di Giacomo, Silvia [2 ]
Di Sotto, Antonella [2 ]
Irannejad, Hamid [3 ]
机构
[1] Iran Univ Med Sci, Razi Drug Res Ctr, Tehran 1545913487, Iran
[2] Sapienza Univ Rome, Dept Physiol & Pharmacol V Erspamer, Ple Aldo Moro 5, I-00185 Rome, Italy
[3] Mazandaran Univ Med Sci, Fac Pharm, Dept Med Chem, Sari 4847116547, Iran
关键词
chalcone; SARS-CoV-2; 3CLpro; PLpro; site-specific inhibitor; host-based targets; MM/PB(GB)SA; PAPAIN-LIKE PROTEASE; SERIES; ACE2; RECEPTOR; POTENT;
D O I
10.3390/ijms24108789
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Previous studies indicated that natural-based chalcones have significant inhibitory effects on the coronavirus enzymes 3CLpro and PLpro as well as modulation of some host-based antiviral targets (HBATs). In this study, a comprehensive computational and structural study was performed to investigate the affinity of our compound library consisting of 757 chalcone-based structures (CHA-1 to CHA-757) for inhibiting the 3CLpro and PLpro enzymes and against twelve selected host-based targets. Our results indicated that CHA-12 (VUF 4819) is the most potent and multi-target inhibitor in our chemical library over all viral and host-based targets. Correspondingly, CHA-384 and its congeners containing ureide moieties were found to be potent and selective 3CLpro inhibitors, and benzotriazole moiety in CHA-37 was found to be a main fragment for inhibiting the 3CLpro and PLpro. Surprisingly, our results indicate that the ureide and sulfonamide moieties are integral fragments for the optimum 3CLpro inhibition while occupying the S1 and S3 subsites, which is fully consistent with recent reports on the site-specific 3CLpro inhibitors. Finding the multi-target inhibitor CHA-12, previously reported as an LTD4 antagonist for the treatment of inflammatory pulmonary diseases, prompted us to suggest it as a concomitant agent for relieving respiratory symptoms and suppressing COVID-19 infection.
引用
收藏
页数:32
相关论文
共 35 条
  • [21] Ligand-based quantitative structural assessments of SARS-CoV-2 3CLpro inhibitors: An analysis in light of structure-based multi-molecular modeling evidences
    Adhikari, Nilanjan
    Banerjee, Suvankar
    Baidya, Sandip Kumar
    Ghosh, Balaram
    Jha, Tarun
    JOURNAL OF MOLECULAR STRUCTURE, 2022, 1251
  • [22] Establishment of a Yeast Two-Hybrid-Based High-Throughput Screening Model for Selection of SARS-CoV-2 Spike-ACE2 Interaction Inhibitors
    Li, Dongsheng
    You, Baoqing
    Guo, Keyu
    Zhou, Wenwen
    Li, Yan
    Wang, Chenyin
    Chen, Xiaofang
    Wang, Zhen
    Zhang, Jing
    Si, Shuyi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (02)
  • [23] Repositioning Therapeutics for SARS-CoV-2: Virtual Screening of Plant-based Anti-HIV Compounds as Possible Inhibitors against COVID-19 Viral RdRp
    Murali, Mahadevamurthy
    Gowtham, Hittanahallikoppal Gajendramurthy
    Ansari, Mohammad Azam
    Alomary, Mohammad N.
    Alghamdi, Saad
    Almehmadi, Mazen
    Singh, Sudarshana Brijesh
    Shilpa, Natarajamurthy
    Aiyaz, Mohammed
    Kalegowda, Nataraj
    Ledesma, Ana E.
    Amruthesh, Kestur Nagaraj
    CURRENT PHARMACEUTICAL DESIGN, 2022, 28 (12) : 969 - 980
  • [24] Cell-Based High-Throughput Screening Protocol for Discovering Antiviral Inhibitors Against SARS-COV-2 Main Protease (3CLpro)
    Hussin A. Rothan
    Teow Chong Teoh
    Molecular Biotechnology, 2021, 63 : 240 - 248
  • [25] Cell-Based High-Throughput Screening Protocol for Discovering Antiviral Inhibitors Against SARS-COV-2 Main Protease (3CLpro)
    Rothan, Hussin A.
    Teoh, Teow Chong
    MOLECULAR BIOTECHNOLOGY, 2021, 63 (03) : 240 - 248
  • [26] Discovery of the covalent SARS-CoV-2 Mpro inhibitors from antiviral herbs via integrating target-based high-throughput screening and chemoproteomic approaches
    Zhang, Ya-Ni
    Zhu, Guang-Hao
    Liu, Wei
    Chen, Xi-Xiang
    Xie, Yuan-Yuan
    Xu, Jian-Rong
    Jiang, Mei-Fang
    Zhuang, Xiao-Yu
    Zhang, Wei-Dong
    Chen, Hong-Zhuan
    Ge, Guang-Bo
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (11)
  • [27] Efficient discovery of potential inhibitors for SARS-CoV-2 3C-like protease from herbal extracts using a native MS-based affinity-selection method
    Zhu, Dafu
    Su, Haixia
    Ke, Changqiang
    Tang, Chunping
    Witt, Matthias
    Quinn, Ronald J.
    Xu, Yechun
    Liu, Jia
    Ye, Yang
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2022, 209
  • [28] A Path-Based Analysis of Infected Cell Line and COVID-19 Patient Transcriptome Reveals Novel Potential Targets and Drugs Against SARS-CoV-2
    Agrawal, Piyush
    Sambaturu, Narmada
    Olgun, Gulden
    Hannenhalli, Sridhar
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [29] Identification of Cyanobacteria-Based Natural Inhibitors Against SARS-CoV-2 Druggable Target ACE2 Using Molecular Docking Study, ADME and Toxicity Analysis
    Niharika Sahu
    Sonal Mishra
    Minu Kesheri
    Swarna Kanchan
    Rajeshwar P. Sinha
    Indian Journal of Clinical Biochemistry, 2023, 38 : 361 - 373
  • [30] Identification of Cyanobacteria-Based Natural Inhibitors Against SARS-CoV-2 Druggable Target ACE2 Using Molecular Docking Study, ADME and Toxicity Analysis
    Sahu, Niharika
    Mishra, Sonal
    Kesheri, Minu
    Kanchan, Swarna
    Sinha, Rajeshwar P.
    INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY, 2023, 38 (03) : 361 - 373